Disclosures

More documents

Recommendations

Info

β-lactams which bind PBP1 enhance PVL production Level of PVL production PVL mRNA fold change No atb OXA IMI CTX CCL FOX Selective ligand : PBP1-4 PBP1 PBP2 PBP3 PBP4 Dumitrescu et al Antimicrob Agents Chemother 2007;51:1515-9 Dumitrescu et al Clin Microbiol Infect 2008; 14: 384–388
Page 1 and 2: Disclosures Research support: Daiic
Page 3 and 4: Facts about nosocomial pneumonia (N
Page 5 and 6: Facts about staphylococcal NP • T
Page 7 and 8: MRSA prolongs ICU stay in VAP, desp
Page 9: Emergency department radiograph
Page 12 and 13: STAPHYLOCOCCAL PNEUMONIA (SP) • P
Page 14 and 15: Virulence Factors • PSM (=phenol
Page 16 and 17: Hayward et al. Emerg Inf Dis. 2008;
Page 18 and 19: MRSA Load in the UK Male age standa
Page 20 and 21: Incidence of Nosocomial pneumonia c
Page 22 and 23: USA • S.aureus in 20% of cases of
Page 24 and 25: Vancomycin MIC creep 80 70 60 MIC
Page 26 and 27: Reduced vancomycin efficacy with hi
Page 28 and 29: Risk Factors for Multidrug-Resistan
Page 30 and 31: Mortality Rates Associated With Ina
Page 32 and 33: Mortality Risk with Increasing Dela
Page 34 and 35: Linezolid vs vancomycin for Gram-po
Page 36 and 37: Wunderink RG, et al. Chest. 2008;13
Page 38 and 39: Not such smart therapy • Vanco in
Page 40 and 41: RECENT STUDIES IN HAP/VAP Tigecycli
Page 42: Following his admission to the inte
Page 45 and 46: Characteristics of pneumonia caused
Page 47 and 48: Clinical features of PVL-associated
Page 49: 350% 300% PVL level reported to con
Page 54 and 55: Guidelines for treatment • Guidel
Page 56 and 57: Remaining issues to be discussed
Page 58: Rubinstein et al. A A C 2003;47:182

Disclosures

Create successful ePaper yourself

Delete template?

Save as template?